Holen Sie sich die Stockscreener-App
21.52
0.00%
0.00
Handel nachbörslich:
22.34
0.82
+3.81%
Schlusskurs vom Vortag:
$21.52
Offen:
$21.31
24-Stunden-Volumen:
274.03K
Relative Volume:
0.57
Marktkapitalisierung:
$1.50B
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-10.06
EPS:
-2.14
Netto-Cashflow:
$23.50M
1W Leistung:
-0.23%
1M Leistung:
+8.41%
6M Leistung:
-10.74%
1J Leistung:
+16.64%
1-Tages-Spanne:
$21.01
$21.66
1-Wochen-Bereich:
$20.84
$22.00
52-Wochen-Spanne:
$15.31
$26.84
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Trading (XNCR) With Integrated Risk Controls - Stock Traders Daily
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - BioSpace
Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor - IPWatchdog.com
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? - Yahoo Finance
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts - Defense World
How to Take Advantage of moves in (XNCR) - Stock Traders Daily
Essex LLC Takes Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Creative Planning Sells 3,356 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
State Street Corp's Strategic Reduction in Xencor Inc Holdings - GuruFocus.com
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know - Yahoo Finance
(XNCR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
AQR Capital Management LLC Invests $753,000 in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy - Simply Wall St
Xencor to begin human trials for bowel disease antibody - Investing.com
Xencor to begin human trials for bowel disease antibody By Investing.com - Investing.com Canada
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases - Business Wire
Blastic Plasmacytoid Dendritic Cell Neoplasm Market By The 2031 | Cellex Patient Treatment GmbH, AbbVie Inc, Xencor, Genentech, Inc, ImmunoGen, Inc – Times-BD24 - Times-BD24
Xencor board member to depart, company seeks new talent - Investing.com
Xencor board member to depart, company seeks new talent By Investing.com - Investing.com South Africa
Xencor Board Member Dagmar Rosa-Bjorkeson to Step Down - TipRanks
Xencor Announces Upcoming Change to Board of Directors - StockTitan
How To Trade (XNCR) - Stock Traders Daily
Xencor’s $175 Million Common Stock Underwritten Public Offering - Global Legal Chronicle
Point72 Asia Singapore Pte. Ltd. Buys New Shares in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Dimensional Fund Advisors LP Has $27.63 Million Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Dimensional Fund Advisors LP Purchases 87,979 Shares of Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Analytical Overview: Xencor Inc (XNCR)’s Ratios Tell a Financial Story - The Dwinnex
Monitoring Xencor Inc (XNCR) after recent insider movements - Knox Daily
Xencor executive sells over $54k in company stock - Investing.com India
Xencor director Richard Ranieri sells over $50k in company stock - Investing.com India
Xencor executive sells over $54k in company stock By Investing.com - Investing.com Australia
Xencor executive sells over $50k in company stock - Investing.com India
Xencor executive Dagmar Rosa-Bjorkeson sells shares worth over $51k - Investing.com
Xencor executive sells over $50k in company stock By Investing.com - Investing.com Canada
Cubist Systematic Strategies LLC Reduces Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Xencor, Inc. (NASDAQ:XNCR) Position Boosted by American Century Companies Inc. - Defense World
Xencor's SWOT analysis: biotech stock's potential in protein engineering - Investing.com
XTX Topco Ltd Acquires New Shares in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Point72 Asset Management L.P. Increases Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Short Interest in Xencor, Inc. (NASDAQ:XNCR) Increases By 24.8% - MarketBeat
Point72 Asia Singapore Pte. Ltd. Acquires New Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Point72 Asset Management L.P. Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xencor Inc-Aktie (XNCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RANIERI RICHARD J | Director |
Sep 27 '24 |
Sale |
20.68 |
2,503 |
51,762 |
8,490 |
| GUSTAFSON KURT A | Director |
Sep 27 '24 |
Sale |
20.68 |
2,503 |
51,762 |
9,490 |
| GORMAN KEVIN CHARLES | Director |
Sep 27 '24 |
Sale |
20.68 |
2,654 |
54,885 |
8,392 |
| Montgomery Alan Bruce | Director |
Sep 27 '24 |
Sale |
20.68 |
1,853 |
38,320 |
9,140 |
| Feigal Ellen | Director |
Sep 27 '24 |
Sale |
20.68 |
2,503 |
51,762 |
8,490 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):